Today: 22 January 2026
Subscribe
Browse Category

NASDAQ:GILD News 20 January 2026

Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

Gilead stock steadies in Wall Street selloff as Bernstein sticks with $135 target and Florida HIV funding shifts loom

New York, Jan 20, 2026, 15:50 EST — Regular session Gilead Sciences shares edged down 0.2% to $124.68 in afternoon trade, after swinging between $122.49 and $126.22 earlier. Bernstein SocGen Group held firm on its Outperform rating and $135 price target, pointing to Yeztugo as a major driver for Gilead’s 2026 forecast. The firm also flagged that the market may…
20 January 2026
···

Stock Market Today

  • Pro Medicus Leverages US Market to Strengthen Competitive Edge in Health-Tech
    January 22, 2026, 5:15 AM EST. Pro Medicus (ASX:PME), known for its advanced radiology imaging software and AI capabilities, is strengthening its position in the US hospital market through long-term contracts. The company competes effectively against larger legacy vendors, supporting its premium valuation despite recent share price declines. Investor focus centers on Pro Medicus' ability to sustain contract wins, margins, and cash flow ahead of its February 12, 2026 earnings report. Market sentiment remains fragile amid high valuation risks and expectations. Divergent fair value estimates, ranging from A$68.65 to over A$500, highlight varying investor perspectives on its growth prospects and US footprint. Pro Medicus' premium positioning in the specialized health-tech arena underpins its broader investment narrative.
Go toTop